Evidence map›Paper›PMID 39735354›Full record

ArticleBME frontiers2024

Recent Advances and Future Directions in Sonodynamic Therapy for Cancer Treatment.

Priyankan Datta, Sreejesh Moolayadukkam, Dhrubajyoti Chowdhury, Adnan Rayes, Nan Sook Lee, Rakesh P Sahu, Qifa Zhou, Ishwar K Puri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BME frontiers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. AnIranian journal of basic medical sciences · 2026
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Priyankan DattaDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA 90089, USA.ORCID https://orcid.org/0000-0002-2899-6714
Sreejesh MoolayadukkamDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Dhrubajyoti ChowdhuryMork Family Department of Chemical Engineering and Material Science, University of Southern California, Los Angeles, CA 90089, USA.
Adnan RayesAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Nan Sook LeeAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Rakesh P SahuDepartment of Materials Science and Engineering, McMaster University, Hamilton, ON L8S 4L8, Canada.
Qifa ZhouAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Ishwar K PuriDepartment of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, CA 90089, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep-tissue solid cancer treatment has a poor prognosis, resulting in a very low 5-year patient survival rate. The primary challenges facing solid tumor therapies are accessibility, incomplete surgical removal of tumor tissue, the resistance of the hypoxic and heterogeneous tumor microenvironment to chemotherapy and radiation, and suffering caused by off-target toxicities. Here, sonodynamic therapy (SDT) is an evolving therapeutic approach that uses low-intensity ultrasound to target deep-tissue solid tumors. The ability of ultrasound to deliver energy safely and precisely into small deep-tissue (>10 cm) volumes makes SDT more effective than conventional photodynamic therapy. While SDT is currently in phase 1/2 clinical trials for glioblastoma multiforme, its use for other solid cancer treatments, such as breast, pancreatic, liver, and prostate cancer, is still in the preclinical stage, with further investigation required to improve its therapeutic efficacy. This review, therefore, focuses on recent advances in SDT cancer treatments. We describe the interaction between ultrasound and sonosensitizer molecules and the associated energy transfer mechanism to malignant cells, which plays a central role in SDT-mediated cell death. Different sensitizers used in clinical and preclinical trials of various cancer treatments are listed, and the critical ultrasound parameters for SDT are reviewed. We also discuss approaches to improve the efficacies of these sonosensitizers, the role of the 3-dimensional spheroid in vitro investigations, ultrasound-controlled CAR-T cell and SDT-based multimodal therapy, and machine learning for sonosensitizer optimization, which could facilitate clinical translation of SDT.

Identifiers

PMID39735354
PMCPMC11671681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.